If You Invested in FRESENIUS MED CARE AG (FMCQF)

FRESENIUS MED CARE AG ORD (trading under the symbol FMCQF) is a foreign private issuer that reports to the U.S. Securities and Exchange Commission under the Securities Exchange Act of 1934. The company files its reports under cover of Form 20-F, which is the standard annual reporting framework for non-U.S. issuers. According to its SEC submissions, the registrant is named Fresenius Medical Care AG, with principal executive offices located in Bad Homburg, Germany.

The company uses Form 6-K to furnish current reports and press releases to U.S. investors. These filings often include exhibits containing press releases, financial figures and other information that the company has disclosed in its home market. For example, multiple 6-K reports reference press releases and financial overviews for specific periods, as well as information furnished under the European Union Market Abuse Regulation.

Fresenius Medical Care AG indicates in its filings that it prepares consolidated financial results in accordance with International Financial Reporting Standards (IFRS). In connection with its quarterly financial communications, the company also presents certain non-GAAP (non-IFRS) financial measures, such as EBITDA, free cash flow, a net leverage ratio and results adjusted for special items or presented in constant currency. The company explains in its filings that these non-GAAP measures are intended to supplement IFRS figures and to provide consistency and comparability with prior periods in which similar measures were reported.

In addition to financial metrics, the company’s disclosures reference several internal reporting and operating concepts. These include references to reportable segments labeled as Health Care Services and Health Care Products, as well as segment descriptors such as Value Based Care, Care Delivery and Care Enablement. The filings also mention arrangements and agreements with related parties, including entities identified as Fresenius SE and its affiliates, as well as other named counterparties.

The company’s SEC filings further refer to instruments and programs such as share buy-back tranches, long-term incentive plans for management, debt issuance programs and various bond issuances. The disclosures also include detailed references to financial liabilities, noncontrolling interests, insurance contracts, and fair value hierarchy levels under IFRS, reflecting the technical accounting framework within which Fresenius Medical Care AG reports.

As a foreign private issuer, Fresenius Medical Care AG uses Form 6-K to provide U.S. investors with interim information, such as quarterly results press releases and accompanying financial statements. These reports may include reconciliations between IFRS figures and the non-GAAP measures used by the company, as well as explanations of how constant currency and adjustments for special items are calculated. The company notes that such non-GAAP measures should not be viewed as substitutes for IFRS measures.

Regulatory reporting and disclosure practices

Fresenius Medical Care AG’s filings indicate an ongoing pattern of furnishing press releases and financial overviews as exhibits to Form 6-K. For example, one filing describes a press release announcing third quarter results for a specified period, accompanied by a complete overview of financial performance for that quarter and the first nine months of the year. Other filings reference press releases and information disclosed under Article 17 of the EU Market Abuse Regulation, which governs the publication of inside information in the European Union.

The company clarifies in its 6-K reports that certain exhibits, including press releases and financial tables, are furnished rather than filed for purposes of Section 18 of the Exchange Act. This distinction means that those exhibits are not automatically incorporated by reference into other registration statements or reports, unless specifically stated.

Business structure and segments as reflected in filings

Within its technical disclosures, Fresenius Medical Care AG references internal segments and business areas using terms such as Health Care Services, Health Care Products, Value Based Care, Care Delivery and Care Enablement. While the filings provided are primarily accounting and reporting oriented, these labels indicate that the company organizes its activities into multiple segments for financial reporting purposes. The filings also refer to operating segments, reportable segments and eliminations of intersegment amounts, consistent with IFRS segment reporting requirements.

In addition, the company’s disclosures mention insurance contracts, reinsurance arrangements, care coordination agreements and related risk adjustment concepts. These references appear in the context of IFRS accounting for insurance contracts, including measurements based on estimates of present value of future cash flows and risk adjustments for non-financial risk.

Use of non-GAAP and non-IFRS measures

In at least one Form 6-K, Fresenius Medical Care AG provides a detailed explanation of its use of non-GAAP financial measures. The company identifies EBITDA, free cash flow, net leverage ratio and constant currency or adjusted results as examples of measures that differ from IFRS metrics. It states that these measures are used to enhance understanding of financial performance and prospects and to provide comparability with prior periods in which similar measures were reported. The filing also notes that reconciliations from these non-GAAP measures to the most comparable IFRS measures are included in the accompanying financial statements or tables.

Location and legal status

According to the SEC filings, Fresenius Medical Care AG is organized as a foreign private issuer with principal executive offices in Bad Homburg, Germany. The filings list a Commission file number and confirm that the company files annual reports under Form 20-F. The documents do not state any change in registration status, delisting or deregistration, and there are no references to Forms 25 or 15-12G in the provided materials.